Key facts
- 52-week range (closes)
- $153.27 – $248.61 Lowest close Oct 16, 2025, highest Sep 3, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- June Fiscal 2026 ended Jun 30, 2026, from SEC filings
- In the S&P 500 since
- May 27, 1997 · All S&P 500 changes
Cardinal Health (CAH) is trading up at $257.55 (+1.94%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Cardinal Health revenue & net income history (FY2017–FY2026)
| FY2017Jun 2017 | FY2018Jun 2018 | FY2019Jun 2019 | FY2020Jun 2020 | FY2021Jun 2021 | FY2022Jun 2022 | FY2023Jun 2023 | FY2024Jun 2024 | FY2025Jun 2025 | FY2026Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $130.0B | $136.8B | $145.5B | $152.9B | $162.5B | $181.3B | $205.0B | $226.8B | $222.6B | $254.2B |
| Growth (year over year) | +6.9% | +5.3% | +6.4% | +5.1% | +6.2% | +11.6% | +13.0% | +10.7% | −1.9% | +14.2% |
| Gross profit | $6.54B | $7.18B | $6.83B | $6.87B | $6.78B | $6.48B | $6.87B | $7.41B | $8.17B | $9.77B |
| Gross margin | 5.0% | 5.2% | 4.7% | 4.5% | 4.2% | 3.6% | 3.4% | 3.3% | 3.7% | 3.8% |
| Operating income | $2.12B | $126.0M | $2.06B | −$4.10B | $472.0M | −$607.0M | $752.0M | $1.24B | $2.27B | $2.61B |
| Operating margin | 1.6% | 0.1% | 1.4% | −2.7% | 0.3% | −0.3% | 0.4% | 0.5% | 1.0% | 1.0% |
| Net income | $1.29B | $256.0M | $1.36B | −$3.70B | $611.0M | −$938.0M | $330.0M | $852.0M | $1.56B | $1.71B |
| Net margin | 1.0% | 0.2% | 0.9% | −2.4% | 0.4% | −0.5% | 0.2% | 0.4% | 0.7% | 0.7% |
| EPS (diluted) | $4.03 | $0.81 | $4.53 | −$12.61 | $2.08 | −$3.37 | $1.26 | $3.45 | $6.45 | $7.23 |
| Balance sheet | ||||||||||
| Cash and equivalents | $6.88B | $1.76B | $2.53B | $2.77B | $3.41B | $4.72B | $4.08B | $5.13B | $3.87B | $4.86B |
| Total assets | $40.1B | $40.0B | $41.0B | $40.8B | $44.5B | $43.9B | $43.3B | $45.1B | $53.1B | $57.3B |
| Total liabilities | $33.3B | $33.9B | $34.6B | $39.0B | $42.8B | $44.8B | $46.3B | $48.3B | $55.8B | $60.0B |
| Long-term debt | $9.07B | $8.01B | $7.58B | $6.76B | $5.37B | $4.74B | $3.91B | $4.66B | $7.98B | $7.00B |
| Shareholders' equity | $6.81B | $6.06B | $6.33B | $1.79B | $1.79B | −$709.0M | −$2.96B | −$3.21B | −$2.78B | −$2.88B |
| Cash flow | ||||||||||
| Operating cash flow | $1.18B | $2.77B | $2.72B | $1.96B | $2.43B | $3.17B | $2.84B | $3.76B | $2.40B | $5.17B |
| Capital expenditure | $387.0M | $384.0M | $328.0M | $375.0M | $400.0M | $387.0M | $481.0M | $511.0M | $547.0M | $649.0M |
| Free cash flow | $797.0M | $2.38B | $2.39B | $1.58B | $2.03B | $2.79B | $2.36B | $3.25B | $1.85B | $4.53B |
| Dividends paid | $577.0M | $581.0M | $577.0M | $569.0M | $573.0M | $559.0M | $525.0M | $499.0M | $494.0M | $491.0M |
| Share buybacks | $600.0M | $550.0M | $600.0M | $350.0M | $200.0M | $1.00B | $2.00B | $750.0M | $765.0M | $1.36B |
| Q4 FY24†Jun 2024 | Q1 FY25Sep 2024 | Q2 FY25Dec 2024 | Q3 FY25Mar 2025 | Q4 FY25†Jun 2025 | Q1 FY26Sep 2025 | Q2 FY26Dec 2025 | Q4 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $59.9B | $52.3B | $55.3B | $54.9B | $60.2B | $64.0B | $65.6B | — |
| Growth (year over year) | +12.1% | −4.3% | −3.8% | +0.0% | +0.5% | +22.4% | +18.8% | — |
| Gross profit | $1.88B | $1.90B | $1.94B | $2.12B | $2.20B | $2.32B | $2.40B | — |
| Gross margin | 3.1% | 3.6% | 3.5% | 3.9% | 3.7% | 3.6% | 3.7% | — |
| Operating income | $401.0M | $568.0M | $549.0M | $730.0M | $428.0M | $668.0M | $707.0M | — |
| Operating margin | 0.7% | 1.1% | 1.0% | 1.3% | 0.7% | 1.0% | 1.1% | — |
| Net income | $235.0M | $416.0M | $400.0M | $506.0M | $239.0M | $450.0M | $467.0M | — |
| Net margin | 0.4% | 0.8% | 0.7% | 0.9% | 0.4% | 0.7% | 0.7% | — |
| EPS (diluted) | $0.93 | $1.70 | — | — | — | $1.88 | — | — |
| Balance sheet | ||||||||
| Cash and equivalents | $5.13B | $2.87B | $3.81B | $3.33B | $3.87B | $4.59B | $2.78B | $4.86B |
| Total assets | $45.1B | $43.1B | $47.0B | $49.9B | $53.1B | $55.2B | $58.1B | $57.3B |
| Total liabilities | $48.3B | $46.3B | $49.9B | $51.8B | $55.8B | $58.0B | $60.8B | $60.0B |
| Long-term debt | $4.66B | $4.22B | $7.06B | $7.14B | $7.98B | $8.98B | $8.35B | $7.00B |
| Shareholders' equity | −$3.21B | −$3.28B | −$2.99B | −$2.95B | −$2.78B | −$2.88B | −$2.88B | −$2.88B |
| Cash flow | ||||||||
| Operating cash flow | $2.08B | −$1.65B | −$396.0M | $2.91B | $1.53B | $973.0M | $686.0M | — |
| Capital expenditure | $193.0M | $90.0M | $99.0M | $126.0M | $232.0M | $108.0M | $131.0M | — |
| Free cash flow | $1.89B | −$1.74B | −$495.0M | $2.79B | $1.29B | $865.0M | $555.0M | — |
| Dividends paid | $122.0M | $128.0M | $122.0M | $124.0M | $120.0M | $129.0M | $122.0M | — |
| Share buybacks | $0 | $375.0M | $15.0M | $375.0M | $0 | $375.0M | $383.0M | — |
From Cardinal Health's 10-K and 10-Q filings with the SEC; its fiscal year ends in June. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Cardinal Health vs the Health Care sector and the S&P 500
Cardinal Health's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Cardinal Health | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +14.2% | +7.1% | +7.0% |
| Net margin, latest fiscal year | 0.7% | 13.1% | 13.0% |
| Dividend per share, latest fiscal year | $2.04 | $2.48 | $2.40 |
| Share price change, 1 year | +63.8% | +22.0% | +7.5% |
Cardinal Health: fiscal year ended June 2026, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Cardinal Health included, are the last regular-session prices of October 20, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/488; the reasons below can overlap. 14 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.
About Cardinal Health
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
Source: Wikipedia — Cardinal Health
- Headquarters
- Dublin, Ohio From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- BDX Becton Dickinson
- BIIB Biogen
- BMY Bristol Myers Squibb
- BSX Boston Scientific
- CI Cigna
- CNC Centene Corporation
- COO Cooper Companies (The)
- COR Cencora